SCHEMBL15917555

SCHEMBL15917555

O=C(O)N[C@H]1CCCN(S(=O)(=O)c2ccccc2Br)C1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.60
USP2 O75604 1/20 0.52
MAPK1 P28482 1/20 0.52
CCR1 P32246 2/20 0.51
HSD11B1 P28845 1/20 0.49
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 2/20 0.46
MMP2 P08253 1/20 0.44
MMP13 P45452 1/20 0.44
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15916980 1.00 EPHX2 (0.60) EPHX2USP2MAPK1CCR1HSD11B1
SCHEMBL15914698 0.93 EPHX2 (0.59) EPHX2USP2MAPK1CCR1KMT2A
SCHEMBL4290145 0.86 EPHX2 (0.78) EPHX2HSD11B1KMT2AALDH1A1POLB
SCHEMBL4290150 0.86 EPHX2 (0.78) EPHX2HSD11B1KMT2AALDH1A1POLB
SCHEMBL15917530 0.85 EPHX2 (0.68) EPHX2KMT2AALDH1A1KDM4EMMP2
SCHEMBL15934176 0.84 ALOX5AP (0.55) EPHX2USP2MAPK1CCR1HSD11B1
SCHEMBL15934210 0.84 ALOX5AP (0.55) EPHX2USP2MAPK1CCR1HSD11B1
SCHEMBL4960500 0.82 EPHX2 (0.79) EPHX2HSD11B1KMT2AALDH1A1POLB
SCHEMBL609034 0.82 EPHX2 (0.79) EPHX2HSD11B1KMT2AALDH1A1POLB
SCHEMBL4010554 0.80 HSD11B1 (0.75) EPHX2USP2MAPK1HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495359-A1 FLAP MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-12 EP disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 EP disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 US disclosed
EP-3070085-A1 FLAP MODULATORS Janssen Pharmaceutica N.V. (BE) 2016-09-21 EP disclosed
EP-2951170-A2 FLAP MODULATORS Janssen Pharmaceutica, N.V. (BE) 2015-12-09 EP disclosed
US-20150259357-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-17 US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed
WO-2014121055-A2 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259357-A1 FLAP MODULATORS PGF, FEN1, TBXA2R EPHX2 945/4885USP2 3691/4885MAPK1 4330/4885
US-20140221311-A1 FLAP MODULATORS PGF, FEN1, TBXA2R EPHX2 945/4885USP2 3691/4885MAPK1 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.